Valneva (NASDAQ:VALN) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Valneva (NASDAQ:VALN) in a research report released on Friday,Benzinga reports. HC Wainwright currently has a $17.00 target price on the stock.

Valneva Stock Performance

NASDAQ:VALN opened at $7.17 on Friday. The firm’s fifty day moving average price is $6.34 and its 200 day moving average price is $5.61. Valneva has a 1-year low of $3.62 and a 1-year high of $9.50. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The firm has a market cap of $582.64 million, a price-to-earnings ratio of -55.15 and a beta of 1.93.

Valneva (NASDAQ:VALN) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). The firm had revenue of $56.48 million during the quarter, compared to analysts’ expectations of $55.64 million. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. On average, sell-side analysts expect that Valneva will post 0.13 EPS for the current year.

Institutional Investors Weigh In On Valneva

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA acquired a new position in Valneva SE (NASDAQ:VALN) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 19,244 shares of the company’s stock, valued at approximately $84,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.